Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/12/2018
SIETES contiene 92610 citas

 
 
 1 a 20 de 47 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta. European Medical Agency 2018:7 de marzo. [Ref.ID 102551]
2. Cita con resumen
Loftus P. Biogen and Abbvie take Multiple sclerosis drug off market. Wall St J 2018:1. [Ref.ID 102466]
3. Cita con resumen
Anónimo. Daclizumab for MS. Drug Ther Bull 2017;55:18-21. [Ref.ID 101403]
4. Cita con resumen
Anónimo. Daclilzumab (Zinbryta) for multiple sclerosis. Med Lett Drugs Ther 2016;58:117-9. [Ref.ID 100792]
5.Enlace a cita original
Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016;354:i3518. [Ref.ID 100715]
6.Tiene citas relacionadas Cita con resumen
Gold R, Glovannoni G, Selmaj KH, Havrdova E, Montalban X, Radue E-W, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G, for the SELECT study investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013;381:2167-75. [Ref.ID 95716]
7.Tiene citas relacionadas
Saldha S, Calabresi PA. Anti-interleukin-2 receptor alpha for multiple sclerosis?. Lancet 2013;381:2141-3. [Ref.ID 95708]
8. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
9. Cita con resumen
Charlish P. The biotech company league table. Scrip Executive Briefing 2008;1:1-12. [Ref.ID 84386]
10.
Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81. [Ref.ID 83496]
11.Tiene citas relacionadas
Ekberg H, Halloran PF. Reduced exposure to calcineurin inhibitors in renal transplantation. The authors reply. N Engl J Med 2008;358:2519-20. [Ref.ID 83148]
12.Tiene citas relacionadas
van den Hoogen M, Hilbrands L. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2008;358:2519. [Ref.ID 83147]
13.Tiene citas relacionadas
Krämer BK, Jung B, Banas B. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2008;358:2519. [Ref.ID 83146]
14.Tiene citas relacionadas
Krüger B, Banas M, Hoffmann U. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2008;358:2519. [Ref.ID 83145]
15.Tiene citas relacionadas
Guba M, Jauch K-W. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2008;358:2518. [Ref.ID 83144]
16.Tiene citas relacionadas
Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, for the ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75. [Ref.ID 81878]
17. Cita con resumen

Se ha producido un error durante la generación de la página

. Understanding monoclonal antibodies. Drug Ther Bull 2007;45:55-6. [Ref.ID 80415]
18.
Sayegh MH, Remuzzi G. Clinical update: immunosuppression minimisation. Lancet 2007;369:1676-8. [Ref.ID 80097]
19.
Sloand EM, Scheinberg P, Maciejewski J, Young NS. Brief communication: successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (declizumab). Ann Intern Med 2006;144:181-5. [Ref.ID 76247]
20. Cita con resumen
Joppi R, Bertele V, Garattini S. Disappointing biotech. BMJ 2005;331:895-7. [Ref.ID 75146]
Seleccionar todas
 
 1 a 20 de 47 siguiente >>